ACR-368 (Prexasertib)
Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Urothelial Carcinoma
Key Facts
Indication
Platinum-Resistant Ovarian Cancer, Endometrial Cancer, Urothelial Carcinoma
Phase
Phase 2
Status
Active
Company
About Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology company leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted therapies matched to patients via predictive OncoSignature tests. Its strategy centers on in-licensing and internally developing small molecule inhibitors, with a lead Phase 2 asset, ACR-368, and a dual-inhibitor clinical candidate, ACR-2316. The company aims to improve therapeutic outcomes by directly profiling the functional protein drivers of cancer, a paradigm shift from traditional genomics.
View full company profile